This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Next Week's Hottest Health Care Stocks

BOSTON ( TheStreet) -- Human Genome Sciences (HGSI), Dendreon (DNDN) and MELA Sciences (MELA - Get Report) each face off against regulators and independent experts next week in a series of separate meetings that will play an important determining role in the future of their respective drugs and medical devices.

The big meetings will unfold over three straight days next week, Nov. 16-18, but the action actually kicks off Friday. What follows is a day-by-day calendar to help investors interesting in following these important meetings.

Friday, Nov. 12
Stock to watch: Human Genome Sciences

The U.S. Food and Drug Administration is expected to post briefing documents for next week's advisory panel set up to review Human Genome's lupus drug Benlysta. These FDA documents will include the agency's review of the drug and the voting questions that will be posed to the panel's independent experts.

The FDA typically posts advisory panel briefing documents in the morning. You'll want to check frequently the FDA's Arthritis Drugs Advisory Committee web site starting around 7:30 am.

Traders will be keying on what the FDA says about Benlysta in its review, which will, of course, impact Human Genome Science's stock price.

Tuesday, Nov. 16
Stocks to watch: Human Genome Sciences and MELA Sciences

The FDA convenes an advisory panel to review Human Genome Science's lupus drug Benlysta, beginning at 8 am. Expect a trading halt in Human Genome all day, which may or may not extend into the after-hours trading session depending on the length of the panel meeting.

I will be live-blogging the Benlysta panel all day, including a real-time, play-by-play of the panel's votes on whether to recommend the drug's approval, which will likely come towards the mid-afternoon. A live link to my blog will be available on Tuesday morning, starting around 7:45 am ET, but you can register now for an email reminder below.

I previewed the Benlysta FDA panel on Monday, which outlines the issues and questions that will likely be raised about the drug's efficacy and safety.

Also on Tuesday, the FDA is expected to post briefing documents for the advisory panel set up to review MELA Sciences' skin cancer detection device MELAFind. Like above, these briefing documents will include the FDA's review of MELAFind and will clearly have a big impact on MELA Sciences trading.

Check the FDA's General and Plastic Surgery Devices Panel web site early Tuesday morning for the MELAFind briefing documents.

Wednesday Nov. 17
Stock to watch: Dendreon

Investor focus will shift from FDA to the Center for Medicare and Medicaid Services (CMS), which is conducting a "national coverage analysis" to determine reimbursement coverage for on-label and off-label use of Dendreon's prostate cancer vaccine Provenge.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
DNDN $0.06 -6.02%
MELA $2.99 0.00%
AAPL $123.25 0.00%
FB $83.30 0.00%
GOOG $548.34 0.00%

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs